Altimmune’s stock plummets over 60% as liver drug falls short in trial

 

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key MASH trial. While it helped with MASH resolution and weight loss, the lack of clear fibrosis improvement spooked investors. Shares crashed over 60%, sending shockwaves through the biotech market. Investors are now waiting for FDA feedback and the next steps for pemvidutide. 

https://economictimes.indiatimes.com/news/international/us/altimmunes-stock-plummets-over-60-as-liver-drug-falls-short-in-trial/articleshow/122093068.cms